Floyd and Serebruany1 hypothesized that prasugrel is a potential cancer promoter based on the results of an analysis of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) data performed by the Food and Drug Administration, which reported an increased incidence of solid cancers in 6813 prasugrel-treated patients compared with 6795 clopidogrel-treated patients. In my opinion, the authors' hypothesis that prasugrel might reduce the natural defense against tumor growth and dissemination by inhibiting P2Y12-dependent platelet function is denied by the same argument that the authors used to prove that tumor promotion is not a class effect.
Cattaneo M. Prasugrel and Cancer. Arch Intern Med. 2010;170(21):1944. doi:10.1001/archinternmed.2010.421